Latest Conference Coverage

CBD Shows Long-Term Safety as Add-On Therapy in Lennox-Gastaut Syndrome

Data presented at the Child Neurology Society Annual Meeting suggest that the safety and efficacy of cannabidiol (Epidiolex; GW Pharmaceuticals) is maintained through 72 weeks of treatment for patients with LGS.

Botox Improves Gait, Pain in Pediatric Patients With Lower Limb Spasticity

The drug recently gained FDA approval for treatment of lower limb spasticity in pediatric patients without cerebral palsy, in which it is associated with improved functional outcomes.

Anup Patel, MD: Transmitting Epilepsy Information Correctly

The associate professor of clinical pediatrics and neurology at Ohio State University and section chief of pediatric neurology at Nationwide Children’s Hospital stresses the importance of broadcasting correct information to the public concerning epilepsy.

Fenfluramine Reduces Frequency of TC Seizures in Dravet Syndrome

A pooled analysis of 2 phase 3 trials of fenfluramine demonstrate the clinical potential of the drug for patients with Dravet syndrome.

Anup Patel, MD: The Realities of Cannabidiol Treatment for Epilepsy

The section chief of pediatric neurology at Nationwide Children’s Hospital discusses the realities parents face when exploring CBD to treat epilepsy.

Mia Minen, MD, MPH: Behavioral Therapies for Posttraumatic Headache

Mia Minen, MD, MPH, sat down for an interview to discuss why behavioral therapies could be an effective and easily accessible treatment for posttraumatic headaches following events like concussions.

Essential Tremor Symptoms, Severity Improved With Cala Trio Neuromodulation Device

The wrist-worn wearable neuromodulation device for essential tremor was shown to be safe and efficacious in the PROSPECT trial, with more than 50% of patients experiencing a ≥50% improvement in tremor "power" or severity.

Mia Minen, MD, MPH: Incorporating Behavioral Treatment for Migraine

At the 2019 American Academy of Neurology Conference, Mia Minen, MD, MPH took the time to sit down and discuss the behavioral therapies associated with treating migraine.

Mia Minen, MD, MPH: Mobile Health in Migraine Treatment

At the 2019 American Academy of Neurology Annual Meeting, Mia Minen, MD, MPH, discussed the opportunities that the increasing number of mobile health users presents for migraine treatment.

Reisa Sperling, MD: Advances in Early Detection of Alzheimer Disease

Sperling sat down with NeurologyLive at AAIC 2019 to discuss her thoughts on efforts to detect and treat Alzheimer early on in the disease.

Marie D'hooghe, MD, PhD: Pregnancy Plans for Patients With MS

The neurologist at the National MS Center and University Hospital, in Brussels, discussed the clinician mindset when treating women with MS who plan to get pregnant, and how patients using assistive reproductive treatments should be approached.

RimabotulinumtoxinB Has Rapid, Long-Lasting Treatment Effect in Sialorrhea

The drug, the only approved botulinum toxin type B on the market, was recently approved for the treatment of chronic sialorrhea in adults.

Jan Hillert, MD, PhD: Stem Cell Transplants in MS

The professor and senior physician in the department of clinical neuroscience at the Karolinska Institutet spoke to the use of stem cell transplantation as a potential method of treating multiple sclerosis.

Mitsubishi Tanabe Reveals Phase 3 Study for Continuous Carbidopa/Levodopa in Parkinson Disease

The clinical development of ND0612 includes 2 doses; a low dose for mid-stage Parkinson patients experiencing loss of motor control on oral therapy, and a high dose for severe disease in which oral drugs are no longer effective.

Inhaled Levodopa Holds Off Dyskinesia in Parkinson Disease

Acorda Therapeutics’ Inbrija, an inhalation powder formulation of levodopa, was associated with no significant increases in troublesome dyskinesia for patients being treated with carbidopa/levodopa.

Amantadine ER Capsules for Dyskinesia Show Consistent Safety, Improved Motor Skills

Data of amantadine (Gocovri, Adamas) extended-release tablets suggested that the therapy is, in fact, safe and tolerable with a unique pharmacokinetic profile, and results in significant improvements in dyskinesia for patients with Parkinson disease.

Pimavanserin Improves Parkinson Disease Depressive Symptoms

Acadia Pharmaceuticals’ pimavanserin significantly improved Hamilton Depression Rating Scale scores for patients with Parkinson disease with depressive symptoms in an 8-week, open-label study.

Tavapadon Posts Positive Phase 2 Results in Early Parkinson Disease

Cerevel Therapeutics’ highly selective dopamine D1/D5 agonist showed significant reductions in UPDRS-III scores for those with early-stage Parkinson disease and is planned to enter phase 3 in 2020.

Danielle Andrade, MD, MSc: Communicating and Network Building in Epilepsy Care

The professor of medicine, neurology, at the University of Toronto shared insight into the importance of communication and a good network of physicians to an adult neurologist caring for patients with epilepsy.

Marie D'hooghe, MD, PhD: Treating Multiple Sclerosis During Pregnancy

The neurologist at the National MS Center and University Hospital, in Brussels, spoke to the decision-making process when treating women with MS who seek to get pregnant, or who are planning a family.

Danielle Andrade, MD, MSc: Education for Adult Neurologists on Pediatric-Onset Epilepsies

The professor of medicine, neurology, at the University of Toronto discussed the best ways for adult neurologists to ensure a smooth transition of care for patients with epilepsy entering their care.

Jan Hillert, MD, PhD: The Blood-Brain Barrier in Multiple Sclerosis

The professor and senior physician in the department of clinical neuroscience at the Karolinska Institutet discussed the evolving understanding of the blood-brain barrier in MS, and what might still be left to uncover.

Achthar Gel Associated With Lower Cost Per Response in Multiple Sclerosis Relapse

Mallinckrodt’s repository corticotropin injection was shown to have a lower cost per patient response compared to other late-line treatments for multiple sclerosis relapses, costing an estimated $148,528 less per response.

Danielle Andrade, MD, MSc: Ensuring Smooth Transitions to Adult Epilepsy Care

The professor of medicine, neurology, at the University of Toronto discussed the best ways for pediatric neurologists to ensure a smooth transition of care for patients with epilepsy who are leaving the pediatric system.

MS Treatment Temelimab (GNbAC1) Shows Sustained 96-Week Efficacy

The GeNeuro agent showed marked reductions in brain atrophy in the thalamus and cerebral cortex through a long-term extension period treating patients with multiple sclerosis.

R. Edward Hogan, MD: Clinician Takeaways for Using Diazepam Nasal Spray

The director of the adult epilepsy center at Washington University in St. Louis discussed the takeaways for clinicians regarding the use of intranasal diazepam as a treatment for runs of seizures in patients with refractory epilepsy.

Jan Hillert, MD, PhD: Treating the Non-Inflammatory Aspects of MS

The professor and senior physician in the department of clinical neuroscience at the Karolinska Institutet spoke to the aspects of MS—such as brain volume loss—which are not currently being addressed by the available disease-modifying therapies.

Relapsing MS Treatment With Natalizumab Linked to High NEDA Rate Over 4 Years

According to new data from STRIVE, 75.4% of those treated with natalizumab achieved overall No Evidence of Disease Activity status by year 4, and no patients had incidence of progressive multifocal leukoencephalopathy.

Siponimod Delays Time to Wheelchair Use in Secondary Progressive MS

After showing significant benefits in delayed disease progression in patients with secondary progressive MS, new data suggests siponimod can delay the time to wheelchair dependence by 4 years.

Ocrelizumab Reduces MS Disease Activity in Patients With Prior DMT Failure

Nearly 87% of patients enrolled in the phase 3b CASTING study had no evidence of disease activity following treatment with ocrelizumab after having an inadequate response to prior DMTs.